Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
TRDA
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q2.23
N/A
-0.78
vs -0.74
Q3.23
+228%
1.02
vs -0.80
Q4.23
N/A
-0.29
vs -0.79
Q1.24
+424%
0.68
vs -0.21
Q2.24
+299%
1.55
vs -0.78
Q3.24
N/A
-0.35
vs 1.02
Q4.24
+110%
0.03
vs -0.29
Q1.25
N/A
-0.42
vs 0.68
Q2.25
N/A
-0.85
vs 1.55
Q3.25
N/A
-0.90
vs -0.35
Sales Growth
YoY
Current
Estimates
Q2.23
NA
18.2M vs NA
Q3.23
NA
43.7M vs NA
Q4.23
NA
41.8M vs NA
Q1.24
+134%
59.1M vs 25.3M
Q2.24
+421%
94.7M vs 18.2M
Q3.24
-55%
19.6M vs 43.7M
Q4.24
-11%
37.4M vs 41.8M
Q1.25
-65%
20.6M vs 59.1M
Q2.25
-90%
9.7M vs 94.7M
Q3.25
-52%
9.4M vs 19.6M
Return on Equity
QoQ
Q2.23
-13%
-0.13
vs -0.03
Q3.23
+14%
0.14
vs -0.13
Q4.23
-4%
-0.04
vs 0.14
Q1.24
+9%
0.09
vs -0.04
Q2.24
+13%
0.13
vs 0.09
Q3.24
-3%
-0.03
vs 0.13
Q4.24
+0%
0
vs -0.03
Q1.25
-4%
-0.04
vs 0
Institutionnal Ownership
QoQ
Q2.23
56
56
vs 53
6%
Q3.23
55
55
vs 56
-2%
Q4.23
62
62
vs 55
13%
Q1.24
76
76
vs 62
23%
Q2.24
83
83
vs 76
9%
Q3.24
101
101
vs 83
22%
Q4.24
105
105
vs 101
4%
Q1.25
109
109
vs 105
4%
globenewswire.com
7 hours ago
globenewswire.com
7 hours ago
zacks.com
9 hours ago
globenewswire.com
16 hours ago
Quote Panel
Key Metrics
Forecast
23%2026-Revenue
-911%2026-EPS
178%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
0.00(-100.00%)
Number of analyst
0
Last analyst upgrade/downgrade
No Data Available
Relative Strength
TRDA
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
NASDAQ
0.50 ( 7.44%)
Relative Strenght
5
Volume Buzz
-17%
Earning Acce
No
Dist 52w H.
67%